Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications detailing the successful degradation of the key cancer target BRD9 via a novel mechanism using DCAF16 E3 ligase.
The company's proprietary Targeted Glues are rationally designed medicines that integrate the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues, while addressing key limitations.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
Author's summary: Amphista Therapeutics publishes breakthrough cancer research.
More News
- Renters’ Rights Bill does not protect tenants only council budgets warns expert
- Delirium Risk Increased for Seniors Prescribed First-Generation Antihistamines
- Which Non-League sides will take part in the Isuzu FA Trophy Second Round Proper? - The Non-League Football Paper
- Let me explain why I think Star Trek: Enterprise is set in J.J. Abrams' Kelvin Timeline
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Tapering Methotrexate Is Feasible in Stable RA With Careful Monitoring
- Community pharmacies and BioPharma: Advancing whole-patient care together
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- BridgeBio to seek approval of limb-girdle drug following new study data
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado